Agenda - Virtual | World Medical Innovation Forum - Gene & Cell Therapy


Opening Remarks

Dr. Klibanski welcomes participants to the 2020 World Medical Innovation Forum, a global — and this year, virtual — gathering of more than 5,000 senior health care leaders. This annual event was established to respond to the intensifying transformation of health care and its impact on innovation. The Forum is rooted in the belief that no matter the magnitude of that change, the center of health care needs to be a shared, fundamental commitment to collaborative innovation – industry and academia working together to improve patient lives. No collaborative endeavor is more pressing than responding to the COVID-19 pandemic.

Scott Sperling, Co-President, Thomas H. Lee Partners; Chairman of the Board of Directors, Mass General Brigham
Anne Klibanski, MD, President & CEO, Mass General Brigham

Care in the Next 18 Months – Routine, Elective, Remote

Hospital chief executives reflect on how health care will evolve over the next 18 months in the face of COVID-19. What will routine health care look like? What about elective surgeries and other interventions? And will care-at-a-distance continue to be an essential component? Simply put, how will we provide manage, and pay for health care in a world forever changed by COVID-19? 

Gregg Meyer, MD, Chief Clinical Officer, Mass General Brigham; Interim President, NWH; Professor of Medicine, HMS
John Fernandez,  President, Mass Eye and Ear and Mass General Brigham Ambulatory Care  
Elizabeth Nabel, MD, President, Brigham Health; Professor of Medicine, HMS
Peter Slavin, MD, President, MGH; Professor, Health Care Policy, HM

COVID-19: Technology Solutions Now and in the Future

Experts leading large teams at the epicenter of the coronavirus outbreak discuss how technology is shaping the pandemic response today and in the coming years. What technology categories are most important? What tools are healthcare organizations, biopharmaceutical companies, and other organizations leveraging to battle this crisis? How will those tools evolve? And, importantly, how can technology inform the medical response to future pandemics? What were the biggest technology surprises in the current response?

Alice Park, Senior Writer, Time
Stephane Bancel, CEO, Moderna
Paul Biddinger, MD, Medical Director for Emergency Preparedness, MGH; Associate Professor of Emergency Medicine, HMS
David Kaufman, MD, PhD, Head of Translational Development, Bill & Melinda Gates Medical Research Institute
Rochelle Walensky, MD, Chief, Infectious Disease, Steve and Deborah Gorlin MGH Research Scholar, MGH; Professor of Medicine, HMS

Digital Health Becomes a Pillar: Tools, Payment, Data

Deployed in the crucible of the coronavirus pandemic, digital health has now become an essential pillar in the delivery of care. Why is that significant? How and why did it happen? What are the essential tools and components? How is the electronic health record and other health data contributing to this digital movement?

Are there novel use cases for telehealth that arose during the first phase of the COVID-19 pandemic? How can digital technologies help enable a full return to work. Thinking ahead to the fall and a possible second wave, are there things we should be doing today to ensure this technology to better detect and profile a resurgence and enhance the patient benefit.

David Louis, MD, Pathologist-in-Chief, MGH; Benjamin Castleman Professor of Pathology, HMS
Alistair Erskine, MD, Chief Digital Health Officer, Mass General Brigham
Adam Landman, MD, VP, Chief Information and Digital Innovation Officer, BH; Associate Professor of Emergency Medicine, HMS
Brooke LeVasseur, CEO, AristaMD
Lee Schwamm, MD, Director, Center for TeleHealth and Exec Vice Chair, Neurology, MGH; Vice President, Virtual Care/Digital Health, Mass General Brigham; Professor, Neurology, HMS

Bayer Pharma Reflections on Innovation: Creating, Collaborating, and Accelerating Discovery During and After a Pandemic

Dr. Moeller will reflect on how Bayer is weathering the organizational challenges posed by the COVID-19 pandemic. How does a global pharmaceutical company continue to drive drug development when its labs are shut down? What are the critical elements needed to keep the engines of innovation firing even in the face of a global public health crisis? How does a global r&d enterprise plan for an uncertain fall 2020 given a potential return of the virus.

John Fish, CEO, Suffolk; Chairman of Board Trustees, Brigham Health
Janet Wu, Bloomberg
Joerg Moeller, MD, PhD, Head of Research & Development, Pharmaceuticals Division, Bayer AG

The Patient Experience During the Pandemic

The coronavirus outbreak is not only testing health care staff and resources, it is also having an overwhelming impact on patients. This panel focuses on the approach and technologies providers are using to address the patient experience along the continuum of care.

Thomas Sequist, MD, Chief Patient Experience and Equity Officer, Mass General Brigham; Professor of Medicine and Health Care Policy, HMS
Anjali Kataria, CEO, Mytonomy
Daniel Kuritzkes, MD, Chief, Division of Infectious Diseases, BH; Harriet Ryan Albee Professor of Medicine, HMS
Peter Lee, PhD, Corporate Vice President, Microsoft Research and Incubation
Jag Singh, MD, PhD, Cardiologist & Founding Director, Resynchronization and Advanced Cardiac Therapeutics Program, MGH; Professor of Medicine, HMS

The Role of AI and Big Data in Fighting COVID-19 and the Next Global Crisis – Successes and Aspirations

AI is a key weapon used to fight COVID-19. What are the biggest successes so far? Which applications show the most promise for the future? Can it help a return to work? Can AI help predict and even prevent the next global health care crisis?

Alice Park, Senior Writer, Time
Mike Devoy, MD, EVP, Medical Affairs & Pharmacovigilance and CMO, Bayer AG
Karen DeSalvo, MD,  Chief Health Officer, Google Health
Keith Dreyer, DO, PhD, Chief Data Science Officer, Mass General Brigham; Vice Chairman, Radiology, MGH; Associate Professor, Radiology, HMS

Designing for Infection Prevention: Innovation and Investment in Personal Protective Equipment and Facility Design

As with many pathogens, prevention is the best defense against SARS-CoV2, the virus that causes COVID-19. Panelists discuss the insights, design strategies, technologies, and practices that are emerging to guard against infection and how those innovations are being applied to protect health care providers and their patients.
Based on what was learned during the spring of 2020, are there specific changes that will lessen morbidity and mortality in a potential a second wave?

Erica Shenoy, MD, PhD, Associate Chief, Infection Control Unit, MGH; Assistant Professor, HMS
Shelly Anderson, SVP, Strategic Initiatives and Partnerships, & Chief Strategy Officer, BH
Michele Holcomb, PhD, EVP, Strategy and Corporate Development, Cardinal Health
Guillermo Tearney, MD, PhD, Remondi Family Endowed MGH Research Institute Chair, Mike and Sue Hazard MGH Research Scholar, MGH; Professor, Pathology, HMS
Teresa Wilson, Director/Architect, Colliers Project Leaders

Preparing for Fall 2020 and Beyond: Production, Innovation, Optimization

How does a global medical technology and life sciences company respond to the health challenges posed by COVID-19? Mr. Murphy reflects on how his organization is working to meet the unprecedented demand for life-saving medical equipment for diagnosing, treating, and managing coronavirus patients. How does a large manufacturer make adjustments to FDA regulated products and supply chains in time to help lessen the impact of a second wave of COVID-19 infections.

Jonathan Kraft, President, The Kraft Group; Chair, Mass General Hospital Board of Trustees
Timothy Ferris, MD, CEO, MGPO; Professor, HMS
Kieran Murphy, CEO, GE Healthcare

Big Tech and Digital Health

Tech giants are dedicating their vast resources to aid in the global response to the coronavirus. This panel will highlight how the big data and computational power of major tech companies is being deployed to help contain the current pandemic through new technologies and services, enable return to work, and how it could help prevent future ones.

Natasha Singer, Reporter, New York Times
Amanda Goltz, Principal, Business Development, Alexa Health & Wellness, Amazon
Michael Mina, MD, PhD, Associate Medical Director, Molecular Virology, BH; Assistant Professor, Epidemiology, Immunology and Infectious Diseases, Harvard Chan School
Marcus Osborne, VP, Walmart Health, Walmart
Jim Weinstein, MD, SVP, Microsoft

Insights on Pandemics and Health Care from the National Security Community

General Alexander, a renowned expert on national security as well as pandemics and health care, reflects on how AI can help identify and predict future global disease outbreaks and enable fully reopening commerce. He also discusses what health care systems can learn from the response to COVID-19 to ensure preparedness for the next infectious disease challenge.

Gregg Meyer, MD, Chief Clinical Officer, Mass General Brigham; Interim President, NWH; Professor of Medicine, HMS
General (Ret) Keith Alexander, Co-CEO, IronNet Cybersecurity

Calibrating Innovation Opportunity and Urgency: Medical and Social

The social and medical needs of patients are deeply intertwined, yet there are significant gaps in the tools and technologies being developed to help address those needs. These are especially apparent in the non-uniform impact of COVID-19. Harnessing opportunities, particularly for patients whose needs fall into the low medical complexity/high social complexity category — a group often overlooked by health care innovators.

Natasha Singer, Reporter, New York Times
Giles Boland, MD, Chair, Department of Radiology, BH; Philip H. Cook Professor of Radiology, HMS
Amit Phadnis, Chief Digital Officer and GE Company Officer, GE Healthcare
Krishna Yeshwant, MD, General Partner, GV; Instructor in Medicine, BH

FDA Role in Managing Crisis and Anticipating the Next

The FDA and other regulatory bodies have played a key role in managing the coronavirus pandemic. How will the agency’s priorities shift in the coming months as community transmission (ideally) slows? What is the FDA’s role in return to work? What is the FDA doing to anticipate future health crises? How will these drive new tools and effect that rate of innovation?

Ravi Thadhani, MD, CAO, Mass General Brigham; Professor of Medicine and Faculty Dean for Academic Programs, HMS
Amy Abernethy, MD, PhD, Principal Deputy Commissioner & Acting CIO, FDA
Lindsey Baden, MD, Director, Clinical Research, Division of Infectious Diseases, BH; Associate Professor, HMS

Keeping Priority on the Biggest Diseases

Biogen CEO Michel Vounatsos discusses how Biogen is tackling some of society’s most devastating neurological and neurodegenerative disorders, and share his perspective on the impact the global COVID-19 pandemic is having on the biopharmaceutical industry.

Jean-François Formela, MD, Partner, Atlas Venture
Michel Vounatsos, CEO, Biogen

Building the Plane While Flying: The Experience of Real-Time Innovation from the Front Line

The COVID-19 crisis has required continuous, real time innovation, impacting the way care is delivered on the front lines and across care continuum. This panel presents the perspective, innovations and experiences of care givers interacting directly with patients across the continuum of care – acute, post-acute, rehab and home care.

Ann Prestipino, SVP; Incident Commander, MGH; Teaching Associate, HMS
Theresa Gallivan, RN, Associate Chief Nurse, MGH
Karen Reilly, DNP, RN, Associate Chief Nursing Officer, Critical Care, Cardiovascular and Surgical Services, BH
Ross Zafonte, DO, SVP, Research Education and Medical Affairs, SRN; Earle P. and Ida S. Charlton Professor of Physical Medicine and Rehabilitation, HMS

CEO Roundtable: Will the Innovation Model Remain as It Was

As we envision a post-COVID-19 world, how will the model for biomedical innovation change? What lessons have been learned? Was this pandemic a once-in-a-lifetime event or should organizations begin to weave pandemic planning into their business and operations strategies? Panelists discuss these and other related questions.

Janet Wu, Bloomberg
Mike Mahoney, CEO, Boston Scientific
Bernd Montag, PhD, CEO, Siemens Healthineers

Emergency and Urgent Care: How COVID-19 Vulnerabilities and Solutions Will Change the Model

How are the roles of emergency medicine and urgent care changing in light of the COVID-19 pandemic? Panelists discuss this topic as well as how current and anticipated new technologies can aid in the delivery of community, urgent, and emergency care now and in the future.

Given a false negative at the point of care has consequences well beyond the patient being treated, does this change what can be offered in the various patient care settings?

Ron Walls, MD, EVP and Chief Operating Officer, BH; Neskey Family Professor of Emergency Medicine, HMS
Troyen Brennan, MD, EVP and CMO, CVS Health
David Brown, MD, Chair, Department of Emergency Medicine, MGH; MGH Trustees Professor of Emergency Medicine, HMS
Julie Lankiewicz, Head, Clinical Affairs & Health Economics Outcomes Research, Bose Health
Michael VanRooyen, MD, Chairman, Department of Emergency Medicine, BH; Director, Humanitarian Initiative, Harvard University; Professor, HMS

Accelerating Diagnostics – Maintaining the Priority: Lab, Home and Digital

COVID-19 diagnostics, a linchpin in controlling viral spread — what caused testing in the U.S. to fall so far behind and how can those missteps be prevented in the future? How do the diagnostics industry, and academic medicine, develop the tests that enable group activities including businesses sports, and community? What is the profile of diagnostic tests coming online in the coming months and into next year? What lessons can be learned to guide the global health community in future disease outbreaks? Given the biological complexity, required performance standards, and immense volume is a simple DTC assays possible on a greatly accelerated timeline.

Jeffrey Golden, MD, Chair, Department of Pathology, BH; Ramzi S. Cotran Professor of Pathology, HMS
James Brink, MD, Chief, Department of Radiology, MGH; Juan M. Taveras Professor of Radiology, HMS
John Iafrate, MD, PhD, Vice Chair, Academic Affairs, MGH; Professor, Pathology, HMS
Celine Roger-Dalbert, VP Diagnostic Assays R&D – Integrated Diagnostic Solutions, BD Life Sciences
Matt Sause, President and CEO, Roche Diagnostics Corporation

Return to Work: Understanding the Technologies and Strategies

Diagnostic testing is a linchpin of the worldwide response to the coronavirus. How does a global leader pivot to develop molecular diagnostics for a novel global pathogen? How does it scale, including managing international supply chains, to provide unprecedented levels of products and services. What are the expectations for return to work and a possible disease spike in fall 2020 or beyond? How will the diagnostics industry be permanently changed?

Peter Markell, EVP, Finance and Administration, CFO & Treasurer, Mass General Brigham
Marc Casper, Chairman, President and CEO, Thermo Fisher Scientific

Digital Therapeutics: Current and Future Opportunities

Digital therapeutics (DTx) represents an emerging class of therapies that is poised for significant growth. Yet already, these software-driven, evidence-based tools for the prevention, management, and/or treatment of disease are already changing patients’ lives. This panel addresses how existing DTx are having an early impact — in the COVID-19 pandemic and — and where current development efforts are headed in the coming years especially if there is a aggressive return of the virus in the fall 2020 or later.

Hadine Joffe, MD, Vice Chair for Research, Department of Psychiatry, Executive Director, Mary Horrigan Connors Center for Women’s Health and Gender Biology, BH; Paula A. Johnson Professor, Women’s Health, HMS
Priya Abani, CEO, AliveCor
Julia Hu, CEO, Lark Health
Dawn Sugarman, PhD, Assistant Psychologist, Division of Alcohol, Drugs, and Addiction, McLean; Assistant Professor, Psychiatry, HMS

Investing During and After the Coronavirus Crisis

The investment environment in life sciences and health care overall was at record levels for most of the last decade. What will this environment look like in the wake of the COVID-19 pandemic – especially over the near to mid-term? Will investor priorities and enthusiasm shift? What is the investor role in developing new coronavisurs tests, vaccines, and therapeutics?

Roger Kitterman, VP, Venture and Managing Partner, Partners Innovation Fund, Mass General Brigham
Jan Garfinkle, Founder & Manager Partner, Arboretum Ventures
Phillip Gross, Managing Director, Adage Capital Management
Christopher Viehbacher, Managing Partner, Gurnet Point Capital

Closing Remarks
Gregg Meyer, MD, Chief Clinical Officer, Mass General Brigham; Interim President, NWH; Professor of Medicine, HMS
 Ravi Thadhani, MD, CAO, Mass General Brigham; Professor of Medicine and Faculty Dean for Academic Programs, HMS

Event Program

Download our event program featuring short stories related to the event, our committees and other information you’ll find prudent for the virtual World Forum.

Gene and Cell Therapy

May 19-21, 2021